The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma

被引:14
作者
Abdi, Jahangir [1 ]
Engels, Ferdi [1 ]
Garssen, Johan [1 ]
Redegeld, Frank [1 ]
机构
[1] Univ Utrecht, Div Pharmacol & Pathophysiol, Dept Pharmaceut Sci, Utrecht Inst Pharmaceut Sci,Fac Sci, NL-3508 TB Utrecht, Netherlands
关键词
Toll-like receptor; Malignant plasma cell; Apoptosis; Heat shock protein; Multiple myeloma; B cell; Osteoclast; Innate immunity; NF-KAPPA-B; TUMOR-CELLS; BONE-MARROW; INDUCED APOPTOSIS; INNATE IMMUNITY; PLASMA-CELLS; OSTEOCLAST DIFFERENTIATION; INTERFERON-ALPHA; DENDRITIC CELLS; GROWTH-FACTOR;
D O I
10.1016/j.critrevonc.2010.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Toll-like receptors are critical structures in sensing the invading pathogens via conserved moieties termed pathogen associated molecular patterns and in directing the innate and adaptive immune responses. Studies have shown that Toll-like receptors are not limited to normal immune cells but are expressed on tumour cells as well, including those of lymphoid neoplasms particularly B-cell malignancies, multiple myeloma and chronic lymphocytic leukemia. Neoplastic plasma cells in multiple myeloma usually show a different pattern of Toll-like receptor expression compared to normal B cells. These receptors on multiple myeloma cells, have been indicated to have a role in their proliferation, differentiation and survival, probably through induction of autocrine IL-6 secretion, and in their immunomodulatory functions. Moreover, it is speculated that these molecules may contribute to osteolytic lesions through activation of osteoclasts, and to angiogenesis through induction of pro-angiogenic factors. Knowledge on Toll-like receptor signalling in the biology of malignant plasma cells or their cellular microenvironment may give new insights into pathogenesis of multiple myeloma and may open new avenues for the therapy of this disease. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:225 / 240
页数:16
相关论文
共 144 条
[1]
Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[2]
Toll-like receptor signalling [J].
Akira, S ;
Takeda, K .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (07) :499-511
[3]
Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival [J].
Alexandrakis, MG ;
Passam, FH ;
Sfiridaki, K ;
Moschandrea, J ;
Pappa, C ;
Liapi, D ;
Petreli, E ;
Roussou, P ;
Kyriakou, DS .
LEUKEMIA RESEARCH, 2004, 28 (03) :259-266
[4]
Activation of toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo [J].
Andreani, Virginia ;
Gatti, Gerardo ;
Simonella, Lucio ;
Rivero, Virginia ;
Maccioni, Mariana .
CANCER RESEARCH, 2007, 67 (21) :10519-10527
[5]
Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors [J].
Arai, F ;
Miyamoto, T ;
Ohneda, O ;
Inada, T ;
Sudo, T ;
Brasel, K ;
Miyata, T ;
Anderson, DM ;
Suda, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (12) :1741-1754
[6]
Asosingh K, 2005, HAEMATOLOGICA, V90, P810
[7]
A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines [J].
Assaf, Areej ;
Esteves, Helia ;
Curnow, S. John ;
Browning, Michael J. .
CELLULAR IMMUNOLOGY, 2009, 259 (01) :90-99
[8]
Hsp90 binds CpG oligonucleotides directly:: implications for Hsp90 as a missing link in CpG signaling and recognition [J].
Bandholtz, L ;
Guo, Y ;
Palmberg, C ;
Mattsson, K ;
Ohlsson, B ;
High, A ;
Shabanowitz, J ;
Hunt, DF ;
Jörnvall, H ;
Wigzell, H ;
Agerberth, B ;
Gudmundsson, GH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (02) :422-429
[9]
Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses [J].
Beg, AA .
TRENDS IN IMMUNOLOGY, 2002, 23 (11) :509-512
[10]
Antiproliferative Properties of Type I and Type II Interferon [J].
Bekisz, Joseph ;
Baron, Samuel ;
Balinsky, Corey ;
Morrow, Angel ;
Zoon, Kathryn C. .
PHARMACEUTICALS, 2010, 3 (04) :994-1015